Kyowa Kirin Co., Ltd. is a Japanese pharmaceutical company that manufactures and sells medical drugs. The company develops antibody-based drugs for the treatment of cancer, kidney disease, and immune system diseases. The Kyowa Kirin Group includes 44 consolidated subsidiaries and 14 equity-method affiliates, with Kirin Holdings Co., Ltd. serving as the parent company. The group operates in the pharmaceutical sector, focusing on specialty medicines to address various health conditions globally.

Summarised from the annual report, fiscal year ended Dec 2025

Industry Drug Manufacturers - Specialty & Generic Homepage kyowakirin.com
Sector Healthcare IR page kyowakirin.com
Tags
antibody-based drugs, oncology, nephrology, immunology, specialty pharmaceuticals, medical drugs, Kyowa Kirin Group, Kirin Holdings Co. Ltd., Orchard Therapeutics Limited
Press page —

Metrics

Valuation  
Market cap ¥ 1.191T
Market cap (USD) $ 7.463B
P/E 13.78
PEG 1.77
P/BV 1.31
P/S 2.24
P/OCF 12.33
P/FCF 90.92
Dividend yield 2.7%
Turnover / mcap —
Returns  
ROE 7.7%
ROI 7.5%
ROIC 7.5%
Profit margin 13.5%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 7.8%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 16.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 496.826B 495.558B 442.233B 398.371B 352.246B 318.352B 305.82B 346.531B 350.728B 343.019B 364.316B 333.446B 340.611B 333.158B
Net profit 67.04B 59.87B 81.188B 53.573B 52.347B 47.027B 67.084B 54.414B 26.355B 18.669B 29.774B 15.898B 30.078B 24.199B
Free cash flow 13.1B -37.384B 82.699B 20.006B 66.782B 4.275B 32.398B — — 36.511B 46.43B — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 2.526K 2.373K 2.371K 2.931K 3.137K 2.813K 2.572K 2.079K 2.18K 1.616K 1.913K 1.135K 1.159K 848.87
Price performance 12m 0.06 0 -0.19 -0.07 0.12 0.09 0.24 -0.05 0.35 -0.16 0.69 -0.02 0.36 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (JPY) 101B — 104B 89B 92.3B 104B 112B 119B 157B 181B
↳ YoY growth -5.5% -14.8% +3.7% +13.0% +7.2% +6.6% +31.9% +15.4%
↳ 5y CAGR +2.7% +12.0% +14.4%
Other receivables (JPY) 5.9B — — — — — — — — —
Borrowings, current (JPY) 5.36B — — — — — — — — —
Cash and deposits (JPY) 13.1B 15.8B 15.9B 20.8B 287B 335B 339B 403B 245B 219B
Intangible assets (JPY) 185B — 58.2B 60.1B 75B 76.1B 64.8B 62.9B 165B 201B
Right-of-use assets (JPY) — — — — — — 20.2B 18.3B 18.3B 24.3B
Net debt (borrowings + leases - cash) (JPY) -7.71B — — — — — — — — —
Cash flow detail
Operating cash flow (JPY) 65.8B 59.8B 56.2B 53.7B 39.5B 86.5B 48.7B 116B 67.9B 96.6B
Purchases of property, plant and equipment (JPY) -20.7B — -4.23B -7.03B -10.1B -6.52B -15.6B -17.2B -26B -37.7B
Purchases of intangible assets (JPY) -8.57B — -9.51B -14.2B -25.1B -13.2B -13.1B -15.6B -79.2B -45.8B
Change in receivables (cash effect) (JPY) 3.72B — -4.49B -642M -5.65B -5.9B -2.7B -2.93B -31.5B -22.4B
Change in inventories (cash effect) (JPY) 6.88B — -4.32B -5.84B -6.59B -8.28B -8.9B -3.31B -1.65B 2.8B
Change in payables (cash effect) (JPY) 178M — 1.42B 2.53B 2.55B -126M -5.87B 4.84B -694M -5.24B
Dividends paid (cash effect) (JPY) -13.7B — -16.1B -21.7B -23.6B -24.2B -25.3B -29B -30.9B -30.9B
Share buybacks (cash effect) (JPY) -8M — -14M -22.6B -14M -23M -11M -10M -40B -9M
Interest paid (cash effect) (JPY) -76M — — — — — — — — —
Income taxes paid (cash effect) (JPY) -18.5B — — — — — — — — —
Operating cash flow before change in receivables (JPY) 62B — 60.7B 54.3B 45.2B 92.4B 51.4B 118B 99.4B 119B
Free cash flow (OCF - PPE - intangibles) (JPY) 36.5B — 42.4B 32.4B 4.28B 66.8B 20B 82.7B -37.4B 13.1B
Income detail
Research and development expense (JPY) 53.8B — 45.7B 53.5B 52.3B 57.7B 62.9B 72.1B 104B 101B
↳ 5y CAGR +9.6% +14.1% +14.1%
Total comprehensive income (JPY) -556M 34B 49.5B 73.2B 43.6B 62.8B 50.7B 102B 85.3B 73.1B
Comprehensive income to owners (JPY) 12.8B 52.5B 49.5B 73.2B 43.6B 62.8B 50.7B 102B 85.3B 73.1B
Reported Mar 16, 2018 Mar 16, 2018 Mar 12, 2020 Mar 12, 2020 Mar 9, 2021 Mar 8, 2022 Mar 12, 2024 Mar 12, 2024 Mar 11, 2025 Mar 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026 Annual Meeting – Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML – – Longer-term Phase 1b data for ziftomenib plus venetoclax and azacitidine in frontline AML support the ongoing Phase 3 KOMET-017 registrational study – – Exploratory analysis to evaluate ziftomenib clinical activity beyond NPM1-mutated and KMT2A-rearranged subtypes – – A total of four oral presentations and four posters to highlight the expanding potential of menin inhibition with ziftomenib across AML treatment settings and combinations – SAN DIEGO and TOKYO, November 4 and 5, 2026 – Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd (TSE: 4151) today announced that eight abstracts related to ziftomenib, including four oral presentations and four posters, have been accepted for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting, taking place December 12-15 in New Orleans. Kura and Kyowa Kirin are working together under a strategic collaboration and license agreement to develop and commercialize ziftomenib for the treatment of acute myeloid leukemia (AML) worldwide. The presentations will include the first clinical results for ziftomenib in combination with the FLT3 inhibitors quizartinib and gilteritinib, longer-term frontline data for ziftomenib plus venetoclax and azacitidine, and an exploratory analysis of ziftomenib activity in molecularly defined AML subtypes beyond NPM1-mutated and KMT2A-rearranged disease. “Our strategy is to establish ziftomenib as a preferred menin inhibitor for combination treatment, supported by clinical evidence across complementary therapeutic approaches,” said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. “Our first clinical results with quizartinib and gilteritinib extend this strategy into FLT3 inhibitor combinations. Together with longer-term venetoclax and azacitidine results and studies of additional combinations, these presentations will help define ziftomenib’s potential as a backbone therapy from initial diagnosis through relapsed or refractory disease.” FLT3 mutations occur in nearly one third of patients with AML and approximately one half of those with an NPM1 mutation. This overlap makes NPM1/FLT3 co-mutated AML an important population for ziftomenib combination development. Two oral presentations will report preliminary safety and clinical activity findings from ziftomenib combinations with FLT3 inhibitors:

1

• KOMET-007: Ziftomenib plus quizartinib and intensive chemotherapy (7+3) in newly diagnosed NPM1/FLT3-ITD co-mutated AML

• KOMET-008: Ziftomenib plus gilteritinib in relapsed or refractory (R/R) NPM1/FLT3 co-mutated AML A poster presentation from KOMET-007 will provide longer-term follow-up on response durability, overall survival, and safety with ziftomenib plus venetoclax and azacitidine in patients with newly diagnosed NPM1-mutated AML who are ineligible for intensive chemotherapy. These findings support the ongoing global, randomized Phase 3 KOMET-017 registrational study evaluating this combination. An exploratory analysis from KOMET-001 will describe clinical activity with ziftomenib monotherapy in patients with R/R AML without NPM1 mutations or KMT2A rearrangements whose disease harbors other genomic alterations associated with MEIS1 expression. The findings support further investigation of ziftomenib in additional molecularly defined AML populations. Two additional oral presentations will feature ziftomenib. The first will report initial results from the PedAL Phase 1 ITCC-101/APAL2020K trial sponsored by Blood Cancer United and Princess Maxima Center evaluating ziftomenib with fludarabine and cytarabine in pediatric R/R acute leukemia. The second will present preclinical findings from additional subsets of menin-associated leukemias. All eight abstracts related to ziftomenib, including those from investigator-sponsored trials, are available on the ASH website. Select 2026 ASH Presentation Details Abstract Title

Abstract Number Ziftomenib combined with gilteritinib for Oral relapsed/refractory NPM1 and FLT3 co-mutated Presentation acute myeloid leukemia (AML): First results from #66 the KOMET-008 phase 1 study

Presentation Details Session 617 December 12 10:45 a.m. CST Great Hall AD

Ziftomenib combined with intensive induction (7+3) and quizartinib for newly diagnosed NPM1-m and FLT3-ITD+ acute myeloid leukemia (AML): Preliminary results from KOMET-007

Oral Presentation #902

Session 617 December 14 3:00 p.m. CST Great Hall BC

Ziftomenib combined with venetoclax/azacitidine in newly diagnosed NPM1-m acute myeloid leukemia (AML): Long-term results from KOMET-007

Poster Presentation #5192

Session 617 December 14 6:00-8:00 p.m. CST Hall F

2

Clinical activity of ziftomenib extends beyond NPM1-mutated and KMT2A-rearranged acute myeloid leukemia (AML) into MEIS1-associated genomic subtypes

Poster Presentation #5190

Session 617 December 14 6:00-8:00 p.m. CST Hall F

Ziftomenib combined with fludarabine and cytarabine in pediatric relapsed/refractory acute leukemia with KMT2A rearrangements, NUP98 rearrangements, or NPM1 mutations: First results of the phase 1 ITCC-101/APAL2020K trial (NCT06376162)

Oral Presentation #666

Session 616 December 13 5:45 p.m. CST Hall B

SETBP1-mutant leukemias depend on MENINassociated KMT2A chromatin complexes to maintain leukemogenic transcriptional programs

Oral Presentation #101

Session 636 December 12 10:30 a.m. CST Hall C

About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved oncedaily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn. About Kyowa Kirin Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, Kyowa Kirin has invested in drug discovery and biotechnology innovation for more than 70 years and is currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hematooncology and rare diseases. A shared commitment to Kyowa Kirin’s values, to sustainable growth, and to making people smile unites Kyowa Kirin across the globe. You can learn more about the business of Kyowa Kirin at www.kyowakirin.com. About KOMZIFTI® (ziftomenib) KOMZIFTI (ziftomenib) is an oral menin inhibitor approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. Ziftomenib is in development for the treatment of frontline and R/R AML harboring NPM1 mutations, KMT2A translocations and FLT3 mutations, with the potential to be combined with approved therapies and benefit a broad spectrum of patients.

3

Prompts

Kyowa Kirin Co., Ltd. (ticker 4151), listed in Japan.

ETFs Holding Kyowa Kirin Co., Ltd.

ETF Weight in ETF Shares Market value As of
AIVI 0.26% 9,600 $ 152.808K Jun 30, 2026
DFIV 0.03% 430,601 $ 6.899M Nov 12, 2026
NTSI 0.03% 8,400 $ 133.707K Jun 30, 2026
DFAI 0.01% 147,300 $ 2.36M Nov 12, 2026
DFSI 0.01% 9,200 $ 147.407K Nov 12, 2026
DFIC 0.01% 116,801 $ 1.871M Nov 12, 2026
DXIV 0.01% 1,800 $ 28.841K Nov 12, 2026
AVDE 0.01% 87,000 $ 1.41M Nov 16, 2026
AVSD 0.01% 1,300 $ 21.07K Nov 16, 2026
DFAX 0.01% 43,900 $ 703.388K Nov 12, 2026